Active Ingredient History
Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum. Pramipexole is used for the treatment of signs and symptoms of idiopathic Parkinson's disease. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Restless Legs Syndrome (approved 1997)
Adrenoleukodystrophy (Phase 4)
Alzheimer Disease (Phase 2)
Amyotrophic Lateral Sclerosis (Phase 2)
Analgesics, Opioid (Phase 2/Phase 3)
Anhedonia (Phase 2)
Binge-Eating Disorder (Phase 3)
Bipolar Disorder (Phase 4)
Chronic Pain (Early Phase 1)
Cocaine-Related Disorders (Phase 1)
Depression (Phase 4)
Depressive Disorder (Phase 3)
Depressive Disorder, Major (Phase 4)
Depressive Disorder, Treatment-Resistant (Phase 4)
Dysthymic Disorder (Phase 2)
Essential Tremor (Phase 3)
Fibromyalgia (Phase 2)
Healthy Volunteers (Phase 4)
Memory Disorders (Phase 4)
Movement Disorders (Early Phase 1)
Obsessive-Compulsive Disorder (Phase 1)
Opioid-Related Disorders (Phase 2/Phase 3)
Parkinsonian Disorders (Phase 2)
Psychotic Disorders (Phase 3)
Renal Colic (Phase 1/Phase 2)
Restless Legs Syndrome (Phase 4)
Schizophrenia (Phase 3)
Sleep Wake Disorders (Phase 2/Phase 3)
Stress Disorders, Post-Traumatic (Phase 3)
Substance-Related Disorders (Phase 1)
Tourette Syndrome (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
